Glitisol

Glitisol is an oral prescription medication whose active ingredient is glibenclamide, a sulfonylurea‑type antidiabetic agent. It is supplied as tablets (strength not specified) and is marketed in the European Union. Glibenclamide stimulates insulin release from pancreatic beta‑cells, helping lower blood glucose in people with type 2 diabetes mellitus. The product should be taken under the guidance of a qualified health professional and regular monitoring of blood glucose levels.

Glitisol (glibenclamide) is indicated for the management of type 2 diabetes mellitus when diet, exercise, and other oral agents are insufficient to achieve glycemic control.

- Used as monotherapy in patients with newly diagnosed type 2 diabetes. - Added to metformin or other oral antidiabetic agents when additional glucose lowering is needed. - May be prescribed in combination with lifestyle modifications to improve overall glycemic control. - Considered for patients who have adequate pancreatic beta‑cell function. - Utilized in clinical practice as a cost‑effective oral hypoglycemic option.

The safety profile of Glitisol reflects the pharmacology of sulfonylureas; side effects range from mild and frequent to rare but serious.

Common: - Mild hypoglycemia, especially if meals are missed or delayed. - Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia. - Headache or dizziness. - Weight gain due to increased insulin activity. - Transient visual disturbances.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions including skin rash, pruritus, or angio‑edema. - Hepatic dysfunction manifested by jaundice or elevated liver enzymes. - Blood dyscrasias such as leukopenia or thrombocytopenia. - Any reaction requiring emergency medical attention.

When prescribing Glitisol, clinicians should evaluate patient-specific factors and monitor for conditions that may increase risk of adverse outcomes.

- Assess renal and hepatic function before initiating therapy. - Use caution in elderly patients due to heightened hypoglycemia risk. - Avoid use in patients with known hypersensitivity to sulfonylureas. - Do not prescribe during pregnancy or lactation unless benefits outweigh potential risks. - Counsel patients to maintain regular meals and monitor blood glucose frequently. - Review concomitant medications that may potentiate hypoglycemia. - Adjust dose or discontinue if recurrent hypoglycemia occurs.

Glitisol can interact with several drugs that affect blood glucose levels or sulfonylurea metabolism.

Avoid: - Concurrent use with other insulin secretagogues (e.g., repaglinide, nateglinide) may cause additive hypoglycemia. - Co‑administration with strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) can increase glibenclamide plasma concentrations. - Combining with high‑dose sulfonylureas or insulin may lead to severe hypoglycemia.

Use with caution: - Beta‑blockers may mask hypoglycemia symptoms; monitor glucose closely. - Thiazide diuretics can raise blood glucose; adjust antidiabetic regimen as needed. - NSAIDs, especially ibuprofen, may impair renal function and affect drug clearance.